Chemotherapy and immunotherapy using monoclonal antibodies have been relatively ineffective for the treatment of brain tumors, in part because of the blood-brain barrier (BBB). Enhanced dose intensity may be achieved by using osmotic BBB disruption (BBBD). During the current funding period, we have reported a multi-institutional series of 174 patients with primary central nervous system lymphoma (PCNSL) treated up front with methotrexate based chemotherapy and BBBD, with a 40% progression free survival at 5 years. This is among the best reported survival for PCNSL in the scientific literature. Improved survival appears to have been achieved without cognitive loss. In the current proposal we hope to improve these results using antibody based therapy in the two compartment model focusing on PCNSL for proof of principle;and to begin extending these concepts to the increasing problem of CNS breast cancer metastasis.
In Aim 1, Mechanisms to improve brain tumor models, we will optimize hematogenous and intracerebrally implanted rat models of human brain tumors.
In Aim 2, Characterization of immunotherapy treatment approaches and neurotoxicity in brain tumor models, the effect of immunotherapy, drug- and radio-immunoconjugates, and combination therapies will be assessed in a new rat intracerebral model of CNS lymphoma (CNSL) and in breast cancer brain metastases models.
In aim 3 we will test whether treatment with the anti-VEGF mAb bevacizumab will prevent vascularization and tumor growth in micrometastatic brain tumors, as a mechanism to approach brain tumor prophylaxis.
In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted. Phase I and II clinical trials will investigate the safety and efficacy of rituximab with chemotherapy after BBBD in newly diagnosed and recurrent PCNSL, and radioimmunotherapy with yttrium-90 labeled anti- CD20 mAb ibritumomab tiuxetan (Zevalin""""""""). We also will characterize neurotoxicity in PCNSL patients who have survived 2+ years in complete response after chemotherapy +/- radiotherapy. In this renewal, we hope to continue to target the BBB using antibodies in a rare primary brain tumor to increase survival and decrease neurotoxicity by avoiding whole brain radiation;and to begin to translate this to CNS breast cancer metastasis, an increasingly common CNS malignancy. This proposal is in response to the Brain Tumor PRG sponsored by NINDS and NCI.

Public Health Relevance

Characterize mechanisms to improve brain tumor models. Evaluate immunotherapy delivery and efficacy, and assess drug immunoconjugates, radioimmunoconjugates, and vascular targeting agents in preclinical brain tumor models. Perform clinical trials of antibody-based therapy and neurotoxicity in human primary central nervous system lymphoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Brain Injury and Neurovascular Pathologies Study Section (BINP)
Program Officer
Timmer, William C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Muehe, Anne M; Feng, Dan; von Eyben, Rie et al. (2016) Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Invest Radiol 51:221-7
Muldoon, Leslie L; Pagel, Michael A; Netto, Joao Prola et al. (2016) Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. J Neurooncol 126:447-54
McConnell, Heather L; Schwartz, Daniel L; Richardson, Brian E et al. (2016) Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine 12:1535-42
Pishko, Gregory L; Muldoon, Leslie L; Pagel, Michael A et al. (2015) Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids Barriers CNS 12:5
Muldoon, Leslie L; Wu, Y Jeffrey; Pagel, Michael A et al. (2015) N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol 121:433-40
Lal, Sangeet; Kersch, Cymon; Beeson, Kathleen A et al. (2015) Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain. PLoS One 10:e0131842
Gahramanov, Seymur; Varallyay, Csanad; Tyson, Rose Marie et al. (2014) Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncol 3:389-400
Doolittle, Nancy D; Muldoon, Leslie L; Culp, Aliana Y et al. (2014) Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol 71:203-43
Landier, Wendy; Knight, Kristin; Wong, F Lennie et al. (2014) Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol 32:527-34
Nasseri, Morad; Gahramanov, Seymur; Netto, Joao Prola et al. (2014) Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol 16:1146-54

Showing the most recent 10 out of 33 publications